Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03979066 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma
A Phase 2 study, sponsored by Gulam Manji.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT03979066 is a Phase 2 study that was terminated before completion, run by Gulam Manji. The registered enrollment target is 1 participants.
The verdict
NCT03979066, a Phase 2 study, was terminated before completion, sponsored by Gulam Manji.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if study treatment with atezolizumab and PEGPH20 given before and after surgery, followed by chemotherapy is safe and if it can further increase the immune response against the tumor rather than increase the chance of cure.
Interventions
- DRUG Atezolizumab
- DRUG PEGPH20
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-11-01 |
| Est. Completion | 2019-11-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03979066
The ClinicalTrials.gov registry entry for NCT03979066 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gulam Manji, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atezolizumab is the first listed.
NCT03979066 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03979066 about?
NCT03979066 is a clinical study titled "Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma". The purpose of this study is to determine if study treatment with atezolizumab and PEGPH20 given before and after surgery, followed by chemotherapy is safe and if it can further increase the immune response against the tumor rather than increase the chance of cure.
What is the current status of trial NCT03979066?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2019-11-01. Estimated completion is 2019-11-03.
What interventions are being tested in trial NCT03979066?
The interventions under investigation include: Atezolizumab (DRUG), PEGPH20 (DRUG).
Who is sponsoring clinical trial NCT03979066?
This trial is sponsored by Gulam Manji, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.